407
Participants
Start Date
December 31, 2005
Primary Completion Date
May 31, 2007
Study Completion Date
January 31, 2012
golimumab
50 mg sc injs every 4 wks from wk 0 thru 5 yrs (unless early escape at wk 16); golimumab - if early escape, 100mg sc injection every 4 wks beginning wk 16 up to 5 yrs; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg
Placebo; golimumab
SC injections ever 4 wks thru Wk 20 (unless early escape at wk 16); golimumab - if early escape, 50mg sc injection from wk 16 up to 5 yrs; golimumab -50mg sc injection beginning Wk 24 up to 5 yrs (unless early escape); golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100 mg
golimumab
100 mg sc injections every 4 wks from wk 0 up to 5 yrs
Huntsville
La Jolla
Upland
Aventura
Coeur d'Alene
Kansas City
Wheaton
Worcester
Omaha
Cincinnati
Mayfield
Lake Oswego
Portland
Duncansville
West Reading
Houston
Edmonds
Seattle
Brussels
Ghent
Leuven
Liège
Merksem
Victoria
Winnipeg
St. John's
North Bay
Ottawa
Toronto
Waterloo
Montreal
Sainte-Foy
Sante Foy
Claire
Hamilton Ontario
Newmarket
Saskatoon
Vancouver
Bialystok
Elblag
Kalisz
Poznan
Szczecin
Torun
Warsaw
Santiago de Compostela
Valencia
Glasgow
London
Middlesbrough
Wigan
Lead Sponsor
Collaborators (1)
Schering-Plough
INDUSTRY
Centocor, Inc.
INDUSTRY